{"id":"https://openalex.org/W2018010296","doi":"https://doi.org/10.1021/jm500228a","title":"Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase","display_name":"Discovery of GS-9973, a Selective and Orally Efficacious Inhibitor of Spleen Tyrosine Kinase","alternate_titles":[],"publication_year":2014,"publication_date":"2014-04-06","ids":{"openalex":"https://openalex.org/W2018010296","doi":"https://doi.org/10.1021/jm500228a","mag":"2018010296","pmid":"https://pubmed.ncbi.nlm.nih.gov/24779514"},"language":"en","primary_location":{"id":"doi:10.1021/jm500228a","doi":"https://doi.org/10.1021/jm500228a","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm500228a","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2018010296"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079048350","display_name":"Kevin Currie","orcid":"https://orcid.org/0000-0002-1716-9799","observed_orcids":["https://orcid.org/0000-0002-1716-9799"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kevin S. Currie","raw_affiliation_strings":["Department of Chemistry, \u2021Department of Biology, and \u00a7Department of Drug Metabolism, Gilead Sciences, Inc. , Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemistry, \u2021Department of Biology, and \u00a7Department of Drug Metabolism, Gilead Sciences, Inc. , Branford, Connecticut 06405, United States","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062549878","display_name":"Jeffrey E. Kropf","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey E. Kropf","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108743594","display_name":"Tony Lee","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tony Lee","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Peter Blomgren","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Peter Blomgren","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058248641","display_name":"Jianjun Xu","orcid":"https://orcid.org/0000-0002-1855-8462","observed_orcids":["https://orcid.org/0000-0002-1855-8462"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jianjun Xu","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100831233","display_name":"Zhongdong Zhao","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhongdong Zhao","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087888745","display_name":"Steve Gallion","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Steve Gallion","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043013411","display_name":"J. Andrew Whitney","orcid":"https://orcid.org/0000-0001-7389-260X","observed_orcids":["https://orcid.org/0000-0001-7389-260X"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Andrew Whitney","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Deborah Maclin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Deborah Maclin","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081461469","display_name":"E.B. Lansdon","orcid":"https://orcid.org/0000-0001-9461-1475","observed_orcids":["https://orcid.org/0000-0001-9461-1475"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric B. Lansdon","raw_affiliation_strings":["Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","Department#R#of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"Department#R#of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022111486","display_name":"Patricia M. Maciejewski","orcid":"https://orcid.org/0000-0003-0760-0861","observed_orcids":["https://orcid.org/0000-0003-0760-0861"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia Maciejewski","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103378384","display_name":"Ann Marie Rossi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ann Marie Rossi","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109052700","display_name":"Hong Rong","orcid":"https://orcid.org/0009-0003-5540-8636","observed_orcids":["https://orcid.org/0009-0003-5540-8636"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Rong","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000114373","display_name":"Jennifer Macaluso","orcid":"https://orcid.org/0009-0005-3441-0395","observed_orcids":["https://orcid.org/0009-0005-3441-0395"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jennifer Macaluso","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"James Barbosa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Barbosa","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051827651","display_name":"Julie A. Di Paolo","orcid":"https://orcid.org/0000-0001-8509-9844","observed_orcids":["https://orcid.org/0000-0001-8509-9844"]},"institutions":[{"id":"https://openalex.org/I4210140816","display_name":"Gilead Sciences (United States)","ror":"https://ror.org/056546b03","country_code":"US","type":"company","lineage":["https://openalex.org/I4210140816"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie A. Di Paolo","raw_affiliation_strings":["Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Informatics & Modeling, Atheon Pharma Inc., Waltham, Massachusetts 02451, United States","institution_ids":[]},{"raw_affiliation_string":"Department of Structural Chemistry, Gilead Sciences, Inc., Foster City, California 94404, United States","institution_ids":["https://openalex.org/I4210140816"]},{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050840284","display_name":"Scott A. Mitchell","orcid":"https://orcid.org/0000-0003-3710-4500","observed_orcids":["https://orcid.org/0000-0003-3710-4500"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Scott A. Mitchell","raw_affiliation_strings":["\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"\u2020 Department of Chemistry, \u2021 Department of Biology, and \u00a7 Department of Drug Metabolism, Gilead Sciences, Inc., Branford, Connecticut 06405, United States","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5050840284"],"corresponding_institution_ids":[],"apc_list":{"value":4500,"currency":"USD","value_usd":4500},"apc_paid":null,"fwci":7.217,"has_fulltext":false,"cited_by_count":184,"citation_normalized_percentile":{"value":0.98123689,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":100},"biblio":{"volume":"57","issue":"9","first_page":"3856","last_page":"3873"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.48240000009536743,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},"topics":[{"id":"https://openalex.org/T10274","display_name":"Heterocyclic Compound Synthesis and Bioactivity","score":0.48240000009536743,"subfield":{"id":"https://openalex.org/subfields/1605","display_name":"Organic Chemistry"},"field":{"id":"https://openalex.org/fields/16","display_name":"Chemistry"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":0.07989999651908875,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.07829999923706055,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/syk","display_name":"Syk","score":0.9819999933242798},{"id":"https://openalex.org/keywords/syk-inhibitors","display_name":"SYK inhibitors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/imidazo-1-2-a-pyrazine","display_name":"imidazo[1,2-a]pyrazine","score":0.9660000205039978},{"id":"https://openalex.org/keywords/fostamatinib","display_name":"fostamatinib","score":0.8180000185966492},{"id":"https://openalex.org/keywords/r406","display_name":"R406","score":0.9559999704360962},{"id":"https://openalex.org/keywords/off-target-toxicity","display_name":"off-target toxicity","score":0.6510000228881836},{"id":"https://openalex.org/keywords/drug-selectivity","display_name":"drug selectivity","score":0.621999979019165},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.9599999785423279},{"id":"https://openalex.org/keywords/kinase-inhibitor-discovery","display_name":"kinase inhibitor discovery","score":0.5899999737739563},{"id":"https://openalex.org/keywords/autoimmune-disease","display_name":"autoimmune disease","score":0.7139999866485596}],"concepts":[{"id":"https://openalex.org/C35174551","wikidata":"https://www.wikidata.org/wiki/Q7660502","display_name":"Syk","level":4,"score":0.9859880208969116},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.643179178237915},{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.6370431184768677},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5034434199333191},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4988715648651123},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.41809841990470886},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.39603191614151},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.38191449642181396},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2859398126602173},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2500086724758148},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.15196526050567627}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002478","descriptor_name":"Cells, Cultured","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D007191","descriptor_name":"Indazoles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D009025","descriptor_name":"Morpholines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009682","descriptor_name":"Magnetic Resonance Spectroscopy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011505","descriptor_name":"Protein-Tyrosine Kinases","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D011719","descriptor_name":"Pyrazines","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D013154","descriptor_name":"Spleen","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D013154","descriptor_name":"Spleen","qualifier_ui":"Q000201","qualifier_name":"enzymology","is_major_topic":false},{"descriptor_ui":"D013329","descriptor_name":"Structure-Activity Relationship","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D021241","descriptor_name":"Spectrometry, Mass, Electrospray Ionization","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D047428","descriptor_name":"Protein Kinase Inhibitors","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D051379","descriptor_name":"Mice","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055808","descriptor_name":"Drug Discovery","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1021/jm500228a","doi":"https://doi.org/10.1021/jm500228a","is_oa":false,"landing_page_url":"https://doi.org/10.1021/jm500228a","pdf_url":null,"source":{"id":"https://openalex.org/S162030435","display_name":"Journal of Medicinal Chemistry","issn_l":"0022-2623","issn":["0022-2623","1520-4804"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","jufo-3","ki-jl-2","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320006","host_organization_name":"American Chemical Society","host_organization_lineage":["https://openalex.org/P4310320006"],"host_organization_lineage_names":["American Chemical Society"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:24779514","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24779514","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of medicinal chemistry","raw_type":"Journal Article"},{"id":"pmh:oai:dora:psi_8846","doi":null,"is_oa":false,"landing_page_url":"https://www.dora.lib4ri.ch/psi/item/psi:8846","pdf_url":null,"source":{"id":"https://openalex.org/S4306402574","display_name":"DORA PSI (Paul Scherrer Institute)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I2802229908","host_organization_name":"Paul Scherrer Institute","host_organization_lineage":["https://openalex.org/I2802229908"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Journal of Medicinal Chemistry","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9391000270843506}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":52,"referenced_works":["https://openalex.org/W95648326","https://openalex.org/W1530812788","https://openalex.org/W1550658501","https://openalex.org/W1781833168","https://openalex.org/W1910349555","https://openalex.org/W1965476653","https://openalex.org/W1976355127","https://openalex.org/W1976402300","https://openalex.org/W1978719672","https://openalex.org/W1979708462","https://openalex.org/W1983116393","https://openalex.org/W1983513155","https://openalex.org/W1987402443","https://openalex.org/W1990105300","https://openalex.org/W2000853637","https://openalex.org/W2008155806","https://openalex.org/W2017341404","https://openalex.org/W2035387891","https://openalex.org/W2040570751","https://openalex.org/W2045549010","https://openalex.org/W2045708448","https://openalex.org/W2047831398","https://openalex.org/W2055091448","https://openalex.org/W2061848933","https://openalex.org/W2066261649","https://openalex.org/W2085313140","https://openalex.org/W2086014281","https://openalex.org/W2086286404","https://openalex.org/W2095255852","https://openalex.org/W2095726706","https://openalex.org/W2100772783","https://openalex.org/W2107431851","https://openalex.org/W2107812240","https://openalex.org/W2107821023","https://openalex.org/W2110956941","https://openalex.org/W2117123429","https://openalex.org/W2118084423","https://openalex.org/W2121448896","https://openalex.org/W2127909394","https://openalex.org/W2129462286","https://openalex.org/W2136060128","https://openalex.org/W2138370786","https://openalex.org/W2142022306","https://openalex.org/W2164596269","https://openalex.org/W2164913505","https://openalex.org/W2171220871","https://openalex.org/W2313920324","https://openalex.org/W2317175743","https://openalex.org/W2320329652","https://openalex.org/W2324715724","https://openalex.org/W2953146212","https://openalex.org/W4210640664"],"related_works":["https://openalex.org/W2317175743","https://openalex.org/W3006648917","https://openalex.org/W2811244860","https://openalex.org/W36847934","https://openalex.org/W4382794581","https://openalex.org/W4393930716","https://openalex.org/W2324715724","https://openalex.org/W2371303488","https://openalex.org/W4396774065","https://openalex.org/W4210855986"],"abstract_inverted_index":{"Spleen":[0],"tyrosine":[1],"kinase":[2],"(Syk)":[3],"is":[4,62,109],"an":[5],"attractive":[6],"drug":[7],"target":[8],"in":[9,32,53,94],"autoimmune,":[10],"inflammatory,":[11],"and":[12,81,103,116],"oncology":[13,117],"disease":[14],"indications.":[15,118],"The":[16],"most":[17],"advanced":[18],"Syk":[19,68,89,106],"inhibitor,":[20],"R406,":[21],"1":[22],"(or":[23],"its":[24,37],"prodrug":[25],"form":[26],"fostamatinib,":[27],"2),":[28],"has":[29,40],"shown":[30],"efficacy":[31],"multiple":[33],"therapeutic":[34,74],"indications,":[35],"but":[36],"clinical":[38,112],"progress":[39],"been":[41,49],"hampered":[42],"by":[43],"dose-limiting":[44],"adverse":[45],"effects":[46],"that":[47,64],"have":[48],"attributed,":[50],"at":[51],"least":[52],"part,":[54],"to":[55],"the":[56,79,95],"off-target":[57],"activities":[58],"of":[59,83,87,97],"1.":[60],"It":[61],"expected":[63],"a":[65,72,84,100],"more":[66],"selective":[67,102],"inhibitor":[69,107],"would":[70],"provide":[71],"greater":[73],"window.":[75],"Herein":[76],"we":[77],"report":[78],"discovery":[80],"optimization":[82],"novel":[85],"series":[86],"imidazo[1,2-a]pyrazine":[88],"inhibitors.":[90],"This":[91],"work":[92],"culminated":[93],"identification":[96],"GS-9973,":[98],"68,":[99],"highly":[101],"orally":[104],"efficacious":[105],"which":[108],"currently":[110],"undergoing":[111],"evaluation":[113],"for":[114],"autoimmune":[115]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2018010296","counts_by_year":[{"year":2026,"cited_by_count":12},{"year":2025,"cited_by_count":12},{"year":2024,"cited_by_count":23},{"year":2023,"cited_by_count":11},{"year":2022,"cited_by_count":16},{"year":2021,"cited_by_count":13},{"year":2020,"cited_by_count":18},{"year":2019,"cited_by_count":12},{"year":2018,"cited_by_count":14},{"year":2017,"cited_by_count":8},{"year":2016,"cited_by_count":20},{"year":2015,"cited_by_count":19},{"year":2014,"cited_by_count":5}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
